مدیفوکسامین

مدیفوکسامین
داده‌های بالینی
نام‌های تجاری	Clédial, Gerdaxyl
نام‌های دیگر	Medifoxamine fumarate; N,N-Dimethyl-2,2-diphenoxyethylamine
روش مصرف دارو	خوراکی
کد ATC	N06AX13 ;
وضعیت قانونی
وضعیت قانونی	℞ (Prescription only);
داده‌های فارماکوکینتیک
زیست فراهمی	۲۱٪
نیمه‌عمر حذف	۲٫۸ ساعت (acute);; ۴٫۰ ساعت (chronic)
شناسه‌ها
	نام آیوپاک N,N-dimethyl-2,2-diphenoxyethanamine;
شمارهٔ سی‌ای‌اس	32359-34-5 ; 16604-45-8 (فوماریک اسید); 16604-44-7 (پیکرات);
پاب‌کم CID	36109;
کم‌اسپایدر	33212;
UNII	KWU7C2A1NT;
KEGG	D07341 ;
CompTox Dashboard (EPA)	DTXSID80186078 ;
ECHA InfoCard	100.046.359
داده‌های فیزیکی و شیمیایی
فرمول شیمیایی	C16H19NO2
جرم مولی	۲۵۷٫۳۳۳ g·mol−1
مدل سه بعدی (جی‌مول)	Interactive image;
	SMILES CN(C)CC(OC1=CC=CC=C1)OC2=CC=CC=C2;
	InChI InChI=1S/C16H19NO2/c1-17(2)13-16(18-14-9-5-3-6-10-14)19-15-11-7-4-8-12-15/h3-12,16H,13H2,1-2H3; Key:QNMGHBMGNRQPNL-UHFFFAOYSA-N;
	(صحت‌سنجی)

مدیفوکسامین(به انگلیسی: Medifoxamine)، که قبلاً با نام‌های تجاری Clédial و Gerdaxyl به فروش می رسید، یک داروی ضدافسردگی غیرمعمول^[۴] با خواص ضد اضطرابی اضافی است.^[۵] این دارو از طریق مکانیسم‌های دوپامینرژیک و سروتونرژیک عمل کرده و قبلاً در فرانسه و اسپانیا و همچنین مراکش به بازار عرضه می شد.^[۶]^[۷]^[۸]^[۹]^[۱۰] مدیفوکسامین برای اولین بار در فرانسه حدود سال ۱۹۹۰ ارائه شد.^[۱۱] با این وجود به دلیل بروز مسمومیت کبدی در سال ۱۹۹۹ از مراکش و ۲۰۰۰ از فرانسه جمع آوری شد.^[۱۲]^[۱۳]^[۱۴]

منابع[ویرایش]

↑ ^۱٫۰ ^۱٫۱ Saleh S, Johnston A, Turner P (October 1990). "Absolute bioavailability and pharmacokinetics of medifoxamine in healthy humans". British Journal of Clinical Pharmacology. 30 (4): 621–4. doi:10.1111/j.1365-2125.1990.tb03823.x. PMC 1368255. PMID 2291875.
↑ ^۲٫۰ ^۲٫۱ Dörwald FZ (4 February 2013). Lead Optimization for Medicinal Chemists: Pharmacokinetic Properties of Functional Groups and Organic Compounds. John Wiley & Sons. pp. 259–. ISBN 978-3-527-64565-7.
↑ Gainsborough N, Nelson ML, Maskrey V, Swift CG, Jackson SH (1994). "The pharmacokinetics and pharmacodynamics of medifoxamine after oral administration in healthy elderly volunteers". European Journal of Clinical Pharmacology. 46 (2): 163–6. doi:10.1007/bf00199882. PMID 8039537. S2CID 6978939.
↑ Holroyd-Leduc, Jayna; Reddy, Madhuri (9 March 2012). Evidence-Based Geriatric Medicine. John Wiley & Sons. pp. 299–. ISBN 978-1-118-28181-9.
↑ Annual Reports in Medicinal Chemistry. Vol. 22. Academic Press. 2 September 1987. pp. 323–. ISBN 978-0-08-058366-2.
↑ Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 759–. ISBN 978-1-4757-2085-3.
↑ Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. pp. 638–. ISBN 978-3-88763-075-1.
↑ Morton IK, Hall JM (31 October 1999). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 173–. ISBN 978-0-7514-0499-9.
↑ Mitchell PB (1995). "Novel French antidepressants not available in the United States". Psychopharmacology Bulletin. 31 (3): 509–19. PMID 8668756.
↑ Consolidated List of Products Whose Consumption And/or Sale Have Been Banned, Withdrawn, Severely Restricted Or Not Approved by Governments. United Nations Publications. 2003. pp. 135–136. ISBN 978-92-1-130230-1.
↑ Saleh S, Johnston A, Edeki T, Turner P (April 1990). "Tolerability and kinetics of intravenous medifoxamine in healthy volunteers". International Clinical Psychopharmacology. 5 (2): 97–102. doi:10.1097/00004850-199004000-00003. PMID 2380545.
↑ Consolidated List of Products Whose Consumption And/or Sale Have Been Banned, Withdrawn, Severely Restricted Or Not Approved by Governments. United Nations Publications. 2003. pp. 135–136. ISBN 978-92-1-130230-1.
↑ Dumortier G, Cabaret W, Stamatiadis L, Saba G, Benadhira R, Rocamora JF, et al. (2002). "[Hepatic tolerance of atypical antipsychotic drugs]". L'Encephale (به فرانسوی). 28 (6 Pt 1): 542–51. PMID 12506267.
↑ Papakostas GI, Fava M (2010). Pharmacotherapy for Depression and Treatment-resistant Depression. World Scientific. pp. 88–. ISBN 978-981-4287-59-3.

[SalehJohnston1990-1] ۱٫۰ ^۱٫۱ Saleh S, Johnston A, Turner P (October 1990). "Absolute bioavailability and pharmacokinetics of medifoxamine in healthy humans". British Journal of Clinical Pharmacology. 30 (4): 621–4. doi:10.1111/j.1365-2125.1990.tb03823.x. PMC 1368255. PMID 2291875.

[Dörwald2013-2] ۲٫۰ ^۲٫۱ Dörwald FZ (4 February 2013). Lead Optimization for Medicinal Chemists: Pharmacokinetic Properties of Functional Groups and Organic Compounds. John Wiley & Sons. pp. 259–. ISBN 978-3-527-64565-7.

[pmid8039537-3] Gainsborough N, Nelson ML, Maskrey V, Swift CG, Jackson SH (1994). "The pharmacokinetics and pharmacodynamics of medifoxamine after oral administration in healthy elderly volunteers". European Journal of Clinical Pharmacology. 46 (2): 163–6. doi:10.1007/bf00199882. PMID 8039537. S2CID 6978939.

[Holroyd-LeducReddy20122-4] Holroyd-Leduc, Jayna; Reddy, Madhuri (9 March 2012). Evidence-Based Geriatric Medicine. John Wiley & Sons. pp. 299–. ISBN 978-1-118-28181-9.

[5] Annual Reports in Medicinal Chemistry. Vol. 22. Academic Press. 2 September 1987. pp. 323–. ISBN 978-0-08-058366-2.

[Elks20142-6] Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 759–. ISBN 978-1-4757-2085-3.

[IndexNominum20002-7] Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. pp. 638–. ISBN 978-3-88763-075-1.

[MortonHall19992-8] Morton IK, Hall JM (31 October 1999). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 173–. ISBN 978-0-7514-0499-9.

[pmid_86687562-9] Mitchell PB (1995). "Novel French antidepressants not available in the United States". Psychopharmacology Bulletin. 31 (3): 509–19. PMID 8668756.

[UnitedNations20032-10] Consolidated List of Products Whose Consumption And/or Sale Have Been Banned, Withdrawn, Severely Restricted Or Not Approved by Governments. United Nations Publications. 2003. pp. 135–136. ISBN 978-92-1-130230-1.

[pmid_2380545-11] Saleh S, Johnston A, Edeki T, Turner P (April 1990). "Tolerability and kinetics of intravenous medifoxamine in healthy volunteers". International Clinical Psychopharmacology. 5 (2): 97–102. doi:10.1097/00004850-199004000-00003. PMID 2380545.

[UnitedNations20033-12] Consolidated List of Products Whose Consumption And/or Sale Have Been Banned, Withdrawn, Severely Restricted Or Not Approved by Governments. United Nations Publications. 2003. pp. 135–136. ISBN 978-92-1-130230-1.

[pmid_125062672-13] Dumortier G, Cabaret W, Stamatiadis L, Saba G, Benadhira R, Rocamora JF, et al. (2002). "[Hepatic tolerance of atypical antipsychotic drugs]". L'Encephale (به فرانسوی). 28 (6 Pt 1): 542–51. PMID 12506267.

[PapakostasFava20102-14] Papakostas GI, Fava M (2010). Pharmacotherapy for Depression and Treatment-resistant Depression. World Scientific. pp. 88–. ISBN 978-981-4287-59-3.

[۱]

[۲]

[۳]

[۴]

[۵]

[۶]

[۷]

[۸]

[۹]

[۱۰]

[۱۱]

[۱۲]

[۱۳]

[۱۴]